The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Taiho Pharmaceutical
 
Allen Lee Cohn
Honoraria - Celgene; onyx; Sanofi
Speakers' Bureau - Celgene; Lilly; Sanofi
 
Radka Obermannova
No Relationships to Disclose
 
Gyorgy Bodoky
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Lilly; Novartis; Roche
Speakers' Bureau - Amgen; Bayer; Lilly; Taiho Pharmaceutical
 
Rocio Garcia-Carbonero
Honoraria - Boehringer Ingelheim (I); Daiichi Sankyo (I); Lilly (I); Pfizer (I); Roche (I)
Consulting or Advisory Role - Boehringer Ingelheim (I); Lilly (I); Pfizer (I); Roche (I)
Travel, Accommodations, Expenses - Amgen (I); Boehringer Ingelheim; Lilly; Merck (I); Roche (I)
 
Tudor-Eliade Ciuleanu
Honoraria - Lilly
 
David Craig Portnoy
No Relationships to Disclose
 
Eric Van Cutsem
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Axel Grothey
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst)
Research Funding - Bayer (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst)
 
Jana Prausová
No Relationships to Disclose
 
Pilar Garcia-Alfonso
Speakers' Bureau - Amgen; Roche
 
Kentaro Yamazaki
Speakers' Bureau - Yakult Pharmaceutical
Research Funding - Lilly
 
Philip R. Clingan
No Relationships to Disclose
 
Vittorina Zagonel
Consulting or Advisory Role - Bayer; Roche
Speakers' Bureau - Amgen; Bayer; Celgene; Merck Serono; Roche; Sanofi
 
Tae Won Kim
Honoraria - Bayer
Consulting or Advisory Role - Abbvie; Bayer
Research Funding - Bayer; Taiho Pharmaceutical
 
Lorinda Simms
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Shao-Chun Chang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Federico Nasroulah
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Takeda
Research Funding - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical